New drugs backed by CHMP include Zavicefta, Zinbryta
On Friday, EMA's CHMP recommended approval of several new drugs, including Zavicefta ceftazidime/avibactam ( CAZ-104), Zinbryta daclizumab, Odefsey rilpivirine/ emtricitabine/tenofovir alafenamide and Ongentys opicapone.
The committee recommended Zavicefta from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat complicated urinary tract infection (cUTIs); complicated intra-abdominal infections (cIAIs); hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP); and some Gram-negative bacterial infections for which there are limited treatment options. The fixed-dose combination of third-generation cephalosporin ceftazidime and broad-spectrum beta lactamase ( LACTB) inhibitor avibactam is approved in the U.S. as Avycaz for cUTIs and cIAIs. ...